A Trial of Vigil for Participants With Ovarian Cancer
Public ClinicalTrials.gov record NCT02346747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is "Will participants who receive treatment with Vigil have a longer time to disease recurrence versus the participants that were not given Vigil?"
Study identification
- NCT ID
- NCT02346747
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2015 (Actual)
- Primary completion
- Dec 2028 (Estimated)
- Completion
- Dec 2028 (Estimated)
- Last update posted
- Oct 29, 2025
2015 – 2028
United States locations
- U.S. sites
- 26
- U.S. states
- 19
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama Mitchell Cancer Institute | Mobile | Alabama | 36604 | — |
| Southern California Permanente Medical Group | Irvine | California | 92618 | — |
| Palo Alto Foundation Medical Group | San Francisco | California | 94115 | — |
| University Of Miami Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| University Of Kentucky Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| Maine Medical Center: MMP Women's Health | Scarborough | Maine | 04074 | — |
| Dana Farber Cancer Institute: Gynecologic Oncology | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Billings Clinic | Billings | Montana | 59101 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87106 | — |
| Duke University Medical Center, Department of Medicine - Oncology | Durham | North Carolina | 27710 | — |
| Barrett Cancer Center University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Stephenson Cancer Center at University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| AMD Asplundh Cancer Pavilion | Abington | Pennsylvania | 19001 | — |
| St. Luke's Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29605 | — |
| Mary Crowley Cancer Research Centers | Dallas | Texas | 75230 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390-9032 | — |
| Cancer Care Northwest | Spokane | Washington | 99216 | — |
| Franciscan Research Center | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02346747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02346747 live on ClinicalTrials.gov.